HEALWELL AI (AIDX): Darwin AI Co-Pilots Identify Over 62,000 High-Risk Patients
Summary
HEALWELL AI says its Darwin-powered AI co-pilots identified over 62,000 high-risk patients in Q2 2026, with 1,291 physicians onboarded, but it has tied no revenue to the tools.
HEALWELL AI (AIDX) said on its second-quarter earnings call on August 7, 2026 that AI co-pilots powered by its Darwin engine identified over 62,000 high-risk patients in the quarter, and that 1,291 physicians have been onboarded [1]. The company has not yet attached any revenue or contract figure to this application.
What HEALWELL AI sells and where the Darwin AI co-pilots fit
HEALWELL AI Inc. (AIDX) is a Toronto-listed healthcare AI and data company. It sells software and data services to hospitals, government health systems and health information exchanges. Its Orion Health unit provides a healthcare data interoperability platform and also serves as the sales channel through which HEALWELL distributes its AI tools.
The AI products are built on the Darwin engine, which the company spells DARWEN. Three kinds of tools sit on top of it: patient identification, chart search and chart summarization. There is also WELL AI Decision Support, a clinical decision support platform operated jointly with WELL Health. The tools are installed inside customers' own electronic medical record systems and care workflows, where frontline physicians and care teams use them. The system screens years of accumulated patient records, flags patients who are at high risk of, or not yet diagnosed with, rare, chronic and complex diseases, and gives the treating physician a searchable summary of the patient's condition with follow-up recommendations. This is the company's core business and is reported in the AI and Data Sciences segment.
Three earnings calls, three steps
The application moved through three steps on three calls within six months.
On March 20, 2026, the story was commercial scale. The capabilities of subsidiaries Khure and Pentavere were folded into a unified Darwin platform, the AI and Data Sciences segment reported 2025 revenue of $10.2 million, up 120% year over year, and paying customers rose to 262 [2].
On May 8, management said the single Darwin engine was complete, Darwin and WELL AI Decision Support were live, and the company had won its first public-sector deployment in the Middle East. It also gave the first application-level output: over the prior six months, the tools had helped identify over 160,000 high-risk patients [3].
By August 7, 2026, the search, summary and identification tools had been packaged as the repeatable Smart Suite, which was deployed in North America, sold in the Middle East and cross-sold into the Orion network. A cross-provincial pilot across three Canadian provinces was completed, and for the first time the output was credited to the AI co-pilots on a single-quarter basis [1]. All three disclosures describe upgrades and channel expansion of the same set of tools. The product was not replaced.
How to read the second-quarter numbers
The second-quarter figures carry weight because both the attribution and the period are clear. The company's president said that in the second quarter alone the AI co-pilots identified over 62,000 high-risk patients, many of whom had not otherwise been flagged for early intervention [1].
Two other numbers need to be read on their own terms. The 1,291 figure is the number of physicians onboarded to the AI co-pilots as of the second quarter, and the company did not disclose how many of them are active users. The 123 figure is the number of rare, complex and chronic conditions the engine is able to screen for. It does not represent the conditions actually detected in the quarter.
The 62,000 figure also cannot be compared with the 160,000 patients over six months cited in May. The periods differ, the May figure also included the contribution of a human team, and on neither occasion did the company give a denominator such as the total number of records screened. No sequential or annualized rate can be derived from the two.
The link to segment revenue is still unproven
Financially, the application is most likely to affect AI and Data Sciences segment revenue, but so far only the March disclosure establishes a partial link. The tools are priced per deployment. A customer starts with a phase-one deployment, for which management in March gave a range of $150,000 to $500,000 for new signings, and expands to an institution-wide enterprise agreement once results are validated. The number of patients identified and the number of physicians onboarded are the evidence a customer uses to decide whether to expand. The possible path runs from validated clinical output, to a larger contract, to contract value recognized as segment revenue.
In March, the chief financial officer attributed the segment's organic growth to commercial adoption of the Khure and Pentavere technology [2]. The same segment also contains a data business serving pharmaceutical and life sciences customers, and the company did not break the two apart.
The August commentary pointed the other way. The chief executive said first-half revenue recognition lagged because of the nature of enterprise sales, and the chief financial officer said full-year segment growth would land at the low end of the earlier range [1]. In the two quarters since March, management has not attached any revenue, contract value, cost or margin figure to the AI co-pilots or Smart Suite. The relationship between clinical output and segment revenue is directional only and has not been demonstrated.
What remains unanswered
HEALWELL has answered whether anyone uses these tools and whether they can find patients. It has not answered how much revenue they bring in each quarter. As sales shift from small pilots to enterprise agreements, revenue recognition moves later. The 62,000 figure for the second quarter can be read only as depth of use, not as growth in revenue, orders or customer count. Judging whether the path works requires the company to disclose, in later quarters, contract value or recurring revenue for Smart Suite or the AI co-pilots themselves, or the number of customers that converted from pilots to enterprise agreements.
Application assessment
- Darwin AI Clinical Detection and Chart Intelligence | Business position: core business | Adoption stage: limited production | Coverage: limited scope | Value type: revenue growth
Sources
[1] Drillr · HEALWELL AI Inc. (AIDX) · 2026-08-07 · Earnings call
Quote: In the second quarter alone, our AI co-pilots powered by our Darwin AI engine identified over 62,000 high risk patients. Patients who in many cases have not otherwise been flagged for early intervention.
[2] Drillr · HEALWELL AI Inc. (AIDX) · 2026-03-20 · Earnings call
Quote: Our AI and data science segment achieved revenue of $10.2 million in 2025, marking a 120% year-over-year growth compared to $4.6 million in 2024.
[3] Drillr · HEALWELL AI Inc. (AIDX) · 2026-05-08 · Earnings call
Quote: over the last six months, our team and incredible technology has helped identify over 160,000 patients that are at high risk for rare, ultra-rare, chronic, and complex conditions.